Kensuke Tomita Cuts Stake in Stemline (4599) to 4.84% | Large Shareholding Report

A large shareholding report (EDINET filing) shows that Kensuke Tomita has reduced his stake in Stemline (4599) to 4.84%. The company engages in research, development, and sales of pharmaceuticals, medical devices, and gene therapy products that activate stem cells to induce the regeneration of damaged tissues. His 4.84% holding positions him as a significant individual shareholder controlling a meaningful portion of the company's market capitalization.

Tomita's initial stake in Stemline was reported at 8.02% on July 7, 2026. Over approximately seven weeks through the August 27 filing date, his holding declined by 1.18 percentage points in a stepwise manner, with four separate large shareholding reports documenting the evolution. The shift from 8.02% to 4.84% represents the disposition of roughly 40% of his initial position, with estimated proceeds totaling ¥270 million.

At the time of execution, the stock was trading at ¥351. As of August 27, Stemline's price-to-book ratio stood at 3.72x, placing the share price at the 94th percentile within the 52-week trading range. The timing suggests a sale into a high valuation environment.

*Speculation: An individual investor systematically reducing his position from two-thirds to less than half over a seven-week period through staged sales may indicate either strategic portfolio rebalancing or the measured realization of capital gains.